New drug duo targets tough lung cancer after first treatment fails
NCT ID NCT07377916
Summary
This study is testing whether combining two targeted drugs, SHR-A1811 and pertuzumab, can help control advanced lung cancer that has a specific genetic change called HER2 and has worsened after at least one prior treatment. About 60 adults with this type of cancer will receive the drug combination to see if it slows cancer growth and is safe. The main goal is to measure how long patients live without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.